Contact

Daria Pašalić
Editor-in-Chief
Department of Medical Chemistry, Biochemistry and Clinical Chemistry
Zagreb University School of Medicine
Šalata ul 2.
10 000 Zagreb, Croatia
Phone +385 (1) 4590 205; +385 (1) 4566 940
E-mail: dariapasalic [at] gmail [dot] com

Useful links

P10-1 (Oral presentation)

Jelisavac Ćosić S, Kulić A, Kovač Z, Vrbanec D, Sirotković-Skerlev M, Jakić-Razumović J. P10-1: Breast cancer cathepsin D expression and survival of patients. Biochemia Medica 2009;19(Suppl 1):S151-S152.
Zagreb University Hospital Center, Zagreb, Croatia
Corresponding author:jelisavaccosic [dot] sanda [at] gmail [dot] com
 
Abstract
 
Background: Cathepsin D is lysosomal aspartic protease upregulated in malignant tissue. Its activity is mitogenic on cancer cells and stromal cells and it may promote metastasic and invasive properties of both types of cells. The aim of this investigation was to correlate survival rate of primary breast cancer patients and cathepsin D antigen levels. It was significant prognostic marker in study with 2810 patients (P < 0.0001, HR = 1.5). In study with 276 patients it was significant for patients who received no adjuvant therapy (N = 119, P = 0.001, RR = 4.0), contrary to group who received adjuvant therapy (N = 52, P > 0.05, RR = 1.2).
Materials and methods: Cathepsin D was determined by RIA in tumor tissue cytosols of 253 patients. Conventional clinicopathological and demographic parameters were gathered. The physicians were aware of cathepsin D lab report. Survival follow-up data were provided by National cancer registry office. In order to estimate relationship of survival rate and cathepsin D antigen levels, Kaplan-Meier survival curves and univariate analysis were calculated. Cut-off value was 45 pmol/mg protein.
Results: The median follow-up time was 90 months. Univariate analysis and Kaplan-Meier survival curves for groups of patients with high and low cathepsin D antigen levels were not significantly different (P = 0.90, HR = 0.97, (95% CI) = 0.62-1.53). In node negative group of patients the results were similar (P = 0.69, HR = 1.21, (95% CI) = 0.47-3.13).
Conclusions: In our study antigen levels of cathepsin D failed to segregate with the breast cancer patients’ survival rates what could be due to altered treatment decision for patients with high cathepsin D levels.
P10-2
Peran N, Slavica V, Meniga D, Pamuković D, Sladić D, Martić A.P10-2: Comparasion of total and complexer PSA in patients with prostatic hyperplasia. Biochemia Medica 2009;19(Suppl 1):S152-S153.
Šibenik General hospital, Šibenik, Croatia
Corresponding author:nena [dot] peran1 [at] gmail [dot] com
 
Abstract
 
Introduction: Prostate Specific Antigen is a glycoprotein produced in the prostate. PSA exist in the blood in two forms: cPSA and fPSA. Increased serum PSA is found in prostate cancer, however it also increases in various benign diseases so tPSA has low specificity. Cases of CaP have been found when PSA was 2.5-4.0 ng/mL which suggest that tPSA has low sensivity. Some studies have shown that majority of tPSA in cancer patients is cPSA (about 85% of tPSA), and have demostrated that cPSA offers improved specifity and sensitivity over tPSA.
Materials and metods: 146 patients with prostatic hyperplasia and tPSA concentrations 2.5-15 ng/mL were included in the study: 56 had tPSA 2.5-4.0 ng/mL; 71 had tPSA 4.0-10 ng/mL, and 19 had tPSA 10-15 ng/mL. Total PSA was measured with both the Advia Centaur (Siemens) and Axsim (Abbott) analyzers; cPSA was measured with the Advia Centaur system.
Results: The results were presented using Spearmans correlation coeffcients and median cPSA/tPSA ratio: r = 0.772 and cPSA/tPSA = 0.70 in group 2.5-4 ng/mL; r = 0.874 and cPSA/tPSA = 0.78 in group 4.0-10.0 ng/mL; r = 0.771 and cPSA/tPSA = 0.83 in group 10.0-15.0 ng/mL. Comparison of tPSA measured with both analyzers shows a high rate of correlation in all group.
Conclusions: The results have shown the existance of corelation betwen cPSA and tPSA in all concentration ranges, especially in range 4.0-10.0 ng/mL. The biggest cPSA/tPSA ratio is in the group of 10.0-15.0 ng/mL, where is the high occurrence of cancer. ADVIA Centaur PSA (Siemens) showes high rate of corelation in determination of Total PSA with Axsym (Abbott) in all concentration ranges.